Henry Schein, Inc.

Henry Schein, Inc.

HSICNYSE / NASDAQHealthcareMid cap

$83.52-$1.28 (-1.5%)

Last close · Data as of Nov 20, 2026

Market cap
$8.7B
P/E
21.8x
EV / EBITDA
12.4x
Revenue
$13.2B
Net margin
3.0%
ROCE
9.5%

+17.3% over the last year

Henry Schein, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-1.4%
3M
-5.6%
6M
+14.1%
1Y
+17.3%
5Y
+9.7%

52-week range

Day change -$1.28 (-1.5%) from $85 to $84 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in HSIC, bought on each weekday since 2021.

News & filings

What Henry Schein filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernRevenue grew 1.4% a year over three years.

Strengths (1)

  • EV / EBITDA of 12.4 against a peer median of 27.5.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments.

Read moreShow less

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Sector
Healthcare
Shares outstanding
121.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$8.7B
P/E
21.8x
P/B
2.7x
EV / EBITDA
12.4x
EV / Sales
0.9x
P/S
0.7x
52-week high
$90.86
52-week low
$68.99

Profitability

Operating margin
5.7%
Net margin
3.0%
EBITDA margin
7.3%
ROE
12.3%
ROCE
9.5%
ROA
3.5%
Asset turnover
1.18

Growth

Revenue
$13.2B
Revenue growth, 1Y
4.0%
Revenue CAGR, 3Y
1.4%
Net profit growth, 1Y
2.1%
Free cash flow
$521.0M

Solvency

Current ratio
1.38
Debt / Equity
1.06
Debt / Assets
0.31
CFO / Net profit
1.79
Cash / Market cap
1.8%

Where the revenue went

Of every $100 of FY2025 revenue, $3 was left as net income.

Henry Schein, Inc. income statement flow, FY2025
Henry Schein, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$9.1B
RevenueGross profit$4.1B
Gross profitSelling, general and administrative$3.1B
Gross profitOther operating expenses$263.0M
Gross profitOperating income$758.0M
Operating incomePretax income$533.0M
Operating incomeInterest and other expense$225.0M
Pretax incomeTax and other$135.0M
Pretax incomeNet income$398.0M

Revenue and net profit

Revenue grew 4.0% in FY2025; net profit is the dashed line.

Henry Schein, Inc. revenue and net profit by fiscal year
Henry Schein, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$12.6B$538.0M
FY2023$12.3B$416.0M
FY2024$12.7B$390.0M
FY2025$13.2B$398.0M

Cash flows

FY2025: $712.0M from operations, $521.0M free after investment (dashed).

Henry Schein, Inc. operating and free cash flow by fiscal year
Henry Schein, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$602.0M$474.0M
FY2023$500.0M$313.0M
FY2024$848.0M$661.0M
FY2025$712.0M$521.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$13.2B+4.0%1Y
EBITDA
$964.0M+5.7%1Y
Net profit
$398.0M+2.1%1Y
Cash from operations
$712.0M-16.0%1Y
Free cash flow
$521.0M-21.2%1Y
Revenue CAGR, 3Y
1.4%
Net profit CAGR, 3Y
-9.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$13.2B$964.0M$398.0M$521.0M12.3%+4.0%+2.1%

Monthly returns

Month-by-month returns of HSIC across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$11.2B
Liabilities$6.4B
Equity$4.8B
Paid-in capital$177.0M
Retained earnings$3.3B
Minority interest$1.5B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; HSIC highlighted.

P/E against peers

HSIC trades at 21.8x earnings against a peer median of 29.9x (a 27% discount).

Not shown (no positive earnings and no EV / Sales): Baxter International Inc., Charles River Laboratories International, Inc., Glaukos Corporation.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Henry Schein, Inc.HSICthis companyP/E ↓ discount$8.7B21.8x2.7x12.3%12.4x
Molina Healthcare, Inc.MOH$10.0B21.3x2.5x11.6%—
Baxter International Inc.BAX$10.0B-10.4x1.6x-15.6%23.2x
Krystal Biotech, Inc.KRYS$9.1B44.3x7.4x16.8%51.2x
Charles River Laboratories International, Inc.CRL$8.9B—2.8x-4.6%27.5x
Bio-Techne CorporationTECH$8.3B113.5x4.3x3.8%39.7x
Corcept Therapeutics IncorporatedCORT$8.0B80.7x12.4x15.4%66.1x
Alkermes plcALKS$7.2B29.9x4.0x13.3%20.9x
Glaukos CorporationGKOS$7.1B-38.1x10.9x-28.6%-49.0x
Peer median—29.9x4.2x7.7%27.5x

Year-to-date ROI

HSIC since 1 January, against earlier years.

Historical volatility

HSIC's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Henry Schein, Inc. operating margin by fiscal year
Henry Schein, Inc. operating margin by fiscal year
DateOperating margin
FY20226.9%
FY20235.6%
FY20245.8%
FY20255.7%
LineFY2025
Cost of revenueCost Of Revenue$9.1B
Gross profitGross Profit$4.1B
Operating expensesOperating Expense$3.3B
Selling, general and administrativeSelling General And Administration$3.1B
Depreciation and amortisationDepreciation And Amortization In Income Statement$263.0M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$263.0M
Total expensesTotal Expenses$12.4B
Pretax incomePretax Income$533.0M

Learn while you research

Academy chapters picked for Henry Schein, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →